ÕÒÂÛÎÄÍø > ҽҩѧÂÛÎÄ > ҽѧÂÛÎÄ >

HA-1Ê÷ͻ״ϸ°ûºËËáÒßÃçµÄ¹¹½¨¼°ÆäÌØÒìÐÔCTLµÄÓÕµ¼(1)

         ×÷ÕߣºÍôÑÄÑÅ£¬ÕŶ«»ª£¬ÁõÎÄÀø£¬ÖܺìÉý£¬ÕÅ·£¬´÷Ãô£¬»ÆÕñÙ»£¬ Ì·»ñ¡¡ÐÜÆ½

¡¾ÕªÒª¡¿  ¡¡¡¡±¾Ñо¿ÒÔ´ÎÒª×éÖ¯ÏàÈÝÐÔ¿¹Ô­HA-1Ϊ°Ðµã£¬¹¹½¨HA-1Ê÷ͻ״ϸ°ûºËËáÒßÃçÓÃÓÚÔìѪ¸Éϸ°ûÒÆÖ²ºó¿¹°×Ѫ²¡ÖÎÁÆ¡£ÌåÍâÅàÑøÒÆÖ²¹©ÕßÊ÷ͻ״ϸ°û£¬ÓÃÁ÷ʽϸ°ûÊõ¡¢»ìºÏÁܰÍϸ°û·´Ó¦¼ì²âÆäÃâÒß»îÐÔ£¬Í¨¹ýµçת·¨½«HA-1»ùÒòתȾÊ÷ͻ״ϸ°û£¬¹¹½¨Ê÷ͻ״ϸ°ûºËËáÒßÃç¡£48Сʱºó¼ì²âHA-1µ°°×±í´ïÇé¿ö¡£½«×ªÈ¾ºóµÄÊ÷ͻ״ϸ°ûÓëͬ»ùÒòÁܰÍϸ°û¹²·õÓýÓÕµ¼ÌØÒìÐÔCTL£¬Ó¦ÓÃLDHÊÍ·ÅʵÑé¼ì²âÆäÌåÍâɱÉË»îÐÔ¡£½á¹û±íÃ÷£º¾­ÍâÖÜѪµ¥ºËϸ°ûÓÕµ¼µÄÊ÷ͻ״ϸ°û±í´ïÊ÷ͻ״ϸ°û±íÐÍ£¬Äܴ̼¤Í¬ÖÖÁܰÍϸ°ûÔöÖ³¡£µçת48Сʱºó£¬Western blot¿É¼ì²âµ½HA-1µ°°×±í´ï¡£ÓÕµ¼µÄCTLÌåÍâɱÉË»îÐÔ¸ßÓÚ¶ÔÕÕ×é¡£½áÂÛ£º´ÎÒª×éÖ¯ÏàÈÝÐÔ¿¹Ô­HA-1¿É×÷ΪÔìѪ¸Éϸ°ûÒÆÖ²ºó¿¹°×Ѫ²¡ÖÎÁƵİе㡣

¡¾¹Ø¼ü´Ê¡¿  Ê÷ͻ״ϸ°û£» HA-1»ùÒò; Ê÷ͻ״ϸ°ûºËËáÒßÃç; ÔìѪ¸Éϸ°ûÒÆÖ²; ϸ°û¶¾ÐÔTÁܰÍϸ°û

¡¡¡¡Construction of HA-1-DC Nucleic-acid Vaccine and Induction of Specific Cytotoxic T Lymphocytes¡¡¡¡
¡¡AbstractThe purpose of this study was to construct a HA-1-DC nucleic acid vaccine and to induce anti-leukemia effect after hematopoietic stem cell transplantation(HSCT). The dendritic cells (DCs) were generated from HSCT donors in vitro, and its immunologic activity was studied by using flow cytometry and mix lymphocyte reaction. HA-1 gene was electroporated into the cultured DCs to construct a DC nucleic acid vaccine. After transfecting for 48 hours, the expression of HA-1 protein was detected by Western blot. The DCs were cultured with isogenic lymphocytes to induce specific cytotoxic T lymphocytes (CTLs). The cytotoxicity of the CTLs was detected by LDH assay. The results showed that the DCs derived from peripheral blood monocytes (PBMCs)  expressed the DC phenotype, and were effective in stimulating proliferation of the allogenic lymphocytes. After electroporating for 48 hours, HA-1 protein was detected by Western blot. The cytotoxity of inducing CTLs was higher than that in the control group. It is concluded that the minor histocompatibility antigen HA-1 can be considered as a target of immunotherapy against leukemia after HSCT.

¡¡¡¡Key wordsdendritic cell£» HA-1 gene£» DC nucleic acid vaccine£» hematopoietic stem cell transplantation£» cytotoxic T lymphocyte

¡¡¡¡Ê÷ͻ״ϸ°û£¨dendritic cell, DC£©ÊÇĿǰÌåÄÚ¹¦ÄÜ×îÇ¿µÄרְ¿¹Ô­³ÊµÝϸ°û£¨antigen presenting cell, APC£©£¬ËüÃÇÄܸßЧÉãÈ¡¡¢´¦Àí¿¹Ô­£¬²¢½«¶àëijʵݸø¾²Ï¢ÐÍTϸ°û£¬ÓÕµ¼ÌØÒìÐÔÃâÒßÓ¦´ð£¬Òò¶ø³ÉΪÖ×ÁöÃâÒßÖÎÁÆÖÐÖØÒªµÄÔËÔØ¹¤¾ß¡£Í¨¹ýת»ùÒò¼¼Êõ£¬½«±àÂëÖ×Áö±íÃæµÄ¿¹Ô­»ùÒòµ¼ÈëDC¹¹½¨ÏàÓ¦µÄºËËáÒßÃ磬ÊǽüÀ´Ö×ÁöÃâÒßÖÎÁƵÄÈȵã£Û1£¬2£Ý¡£Òì»ùÒòÔìѪ¸Éϸ°ûÒÆÖ²£¨allogeneic hemato- poietic stem cell transplantation, allo-HSCT£© ÊÇÖÎÁư×Ѫ²¡×îÓÐЧµÄ·½·¨£¬ µ«ÒÆÖ²ºóÒÆÖ²ÎËÞÖ÷²¡(graft versus host disease, GVHD)ºÍ¸´·¢ÑÏÖØÓ°ÏìÁ˲¡È˵Ĵæ»îÂÊ¡£ÈçºÎÔöÇ¿ÒÆÖ²Î°×Ѫ²¡£¨graft versus leukemia, GVL£©Ð§Ó¦£¬¼õÉÙ¸´·¢Í¬Ê±ÓÖ²»ÓÕ·¢GVHD£¬ÊÇÒÆÖ²³É¹¦µÄ¹Ø¼ü¡£ÏÞÖÆÐÔ±í´ïÓÚÔìѪ¸Éϸ°ûºÍ°×Ѫ²¡Ï¸°û±íÃæµÄ´ÎÒª×éÖ¯ÏàÈÝÐÔ¿¹Ô­£¨minor histocompatibility antigens, mHags£©ÔÚ·ÖÀëGVLºÍGVHDÖÐÆðÖØÒªµÄ×÷ÓãÛ3£Ý¡£ Òò´Ë£¬ ±¾ÊµÑéÓ¦ÓÃHA-1»ùÒò¹¹½¨ÕæºË±í´ïÔØÌ壬תȾDC£¬ÓÕµ¼ÌØÒìÐÔϸ°û¶¾ÐÔTÁܰÍϸ°û£¨cytotoxic T lymphocytes, CTLs£©£¬·¢»Ó¿¹°×Ѫ²¡Ð§Ó¦¡£

¡¡¡¡²ÄÁϺͷ½·¨

¡¡¡¡²ÄÁÏ

¡¡¡¡ÈËÖØ×éIL-4ºÍGM-CSF¾ù¹º×ÔPeprotech¹«Ë¾£¬ÁܰÍϸ°û·ÖÀëÒº¹º×ÔÉϺ£ÊÔ¼Á¶þ³§£¬RPMI 1640¡¢Ë¿ÁÑÃ¹ËØC¡¢MTT¾ùΪSigma¹«Ë¾²úÆ·£¬Ì¥Å£ÑªÇ壨FCS£©¹º×Ôº¼ÖÝËļ¾Ç幫˾¡£PE±ê¼ÇµÄÊó¿¹È˵¥¿Ë¡¿¹ÌåCD80ºÍCD14¡¢FITC±ê¼ÇµÄÊó¿¹È˵¥¿Ë¡¿¹ÌåCD83ºÍCD86¼°Í¬ÐͶÔÕÕ¾ù¹º×ÔeBioscience¹«Ë¾¡£Xba¢ñºÍBamH¢ñÏÞÖÆÐÔÄÚÇÐø¡¢1 kb DNA Marker¹º×ÔMBI¹«Ë¾¡£½º»ØÊÕ¡¢ÖÊÁ£Ð¡Ìá¡¢´óÌáÊÔ¼ÁºÐ¾ù¹º×ÔÉϺ£»ªË´¹«Ë¾¡£T4DNAÁ¬½ÓøΪPromega¹«Ë¾²úÆ·¡£¿¹hisµ¥¿Ë¡¿¹Ì幺×ÔNovagen¹«Ë¾¡£ÈËIL-2¹º×Ô±±¾©ËÄ»·ÉúÎïÖÆÆ·³§¡£pcDNA3.1/hisAºÍpEGFP-C1 ÓÉÎÒÔº¸¾¿ÆÖ×ÁöÖÐÐij¸ղ©Ê¿»ÝÔù£¬pcDNA3.1-HA-1ÓɺÉÀ¼ÀÕµÇ(Leiden)´óѧҽѧÖÐÐÄDr.Prof.E.A.J.M.Goulmy»ÝÔù¡£Á÷ʽϸ°ûÒÇ£¨Becton Dickinson¹«Ë¾²úÆ·£©£¬µçתÒÇ£¨ECM2001 BTX¹«Ë¾²úÆ·£©£¬µçת±­£¨8mmgap,GTS¹«Ë¾²úÆ·£©£¬Ã¸±êÒÇ£¨Biotech¹«Ë¾²úÆ·£©¡£

¡¡¡¡·½·¨

¡¡¡¡DCÌåÍâÅàÑøÈ¡HA-1ÒõÐÔ±í´ïµÄÒÆÖ²¹©ÕßÍâÖÜѪ£¬ÓÃÁܰÍϸ°û·ÖÀëÒº·ÖÀë³öµ¥¸öºËϸ°û£¬PBSҺϴµÓ3´Î£¬ÓÃRPMI 1640ÅàÑøÒºÐü¸¡Ï¸°û£¬°´5¡Á106/ml½ÓÖÖÓÚ6¿×°åÖУ¬Ã¿¿×2 ml£¬ÖÃ37¡æ¡¢5£¥ CO2ÅàÑøÏäÖÐÅàÑø2Сʱ£¬ÇáÇá´µ´òÈ¥³ýÐü¸¡Ï¸°û£¬¼´»ñµÃÌù±ÚµÄÍâÖÜѪµ¥ºËϸ°û£¨PBMC£©£¬Ã¿¿×¼ÓÈë2 mlº¬10£¥FCSµÄRPMI 1640ÅàÑøÒº£¬¼ÓÈëϸ°ûÒò×ÓrhGM-CSF 100 ng/ml¼°rhIL-4  40 ng/ml¡£¸ôÌì°ëÁ¿»»Òº£¬²¹³äϸ°ûÒò×Ó¡£ÓÚÅàÑøµÚ7ÌìÊÕ¼¯Ðü¸¡Ï¸°û¡£
Á÷ʽϸ°ûÊõ·ÖÎö±íÐÍDCÐüÒºÓÃPBSҺϴµÓ2´Î£¬µ÷Õûϸ°ûŨ¶ÈΪ1¡Á106/ml£¬¼ÓÈëEppendorf¹Ü£¬Ã¿¹Ü100 ¦Ìl£¬ÔÙ·Ö±ð¼ÓÈëPE±ê¼ÇµÄCD80¡¢CD14¼°FITC±ê¼ÇµÄCD83¡¢CD86£¬4¡æ±Ü¹â·õÓý30·ÖÖÓ£¬PBSҺϴµÓ£¬1£¥¶à¾Û¼×È©¹Ì¶¨ºóÉÏÁ÷ʽϸ°ûÒǼì²â¡£

¡¡¡¡Í¬ÖÖ»ìºÏÁܰÍϸ°û·´Ó¦·ÖÀ뽡¿µÈËÍâÖÜѪ»ñµÃµ¥¸öºËϸ°û£¬ÔÚÅàÑøÏäÖÐÅàÑø2Сʱ£¬ÊÕ¼¯Ðü¸¡Ï¸°û¼´Í¬ÖÖÒìÌåÁܰÍϸ°û×÷Ϊ·´Ó¦Ï¸°û£¬´Ì¼¤Ï¸°û£¨DC¼°Í¬»ùÒòµÄPBMC£©ÓÃÍêÈ«ÅàÑøÒºµ÷ÕûŨ¶ÈΪ1¡Á106/ml£¬¼ÓÈëÖÕŨ¶È25 ¦Ìg/mlµÄË¿ÁÑÃ¹ËØC£¬37¡æ·õÓý30·ÖÖÓ£¬PBSҺϴµÓ3´Î£¬Óú¬8£¥FCSµÄRPMI 1640ÅàÑøÒºÐü¸¡µ÷ÕûŨ¶È£¬·Ö±ðÒÔ1¡Á103/¿×¡¢5¡Á103/¿×ºÍ1¡Á104/¿×¼ÓÈë96¿×°åÖУ¬Ã¿×éÉè3¸ö¸´¿×£¬Ã¿¿×ÔÙ¼ÓÈë1¡Á105·´Ó¦Ï¸°û£¬ÖÕÌå»ýΪ200 ¦Ìl£¬ÒÔδ¼Ó´Ì¼¤Ï¸°ûµÄÁܰÍϸ°ûΪÒõÐÔ¶ÔÕÕ¡£37¡æ¡¢5£¥ CO2 ÅàÑø72Сʱ£¬Ã¿¿×¼ÓÈë20 ¦Ìl   MTT(5    mg/ml)£¬±Ü¹â37¡æÎÂÏäÖзõÓý4Сʱ£¬ÀëÐÄÈ¥ÉÏÇ壬ÿ¿×¼ÓÈë200 ¦Ìl  DMSO,È¡²¨³¤570 nm¼ì²âA570Öµ¡£½á¹ûÓÃ3¿×¾ùÖµ±íʾ¡£

¡¡¡¡´Ì¼¤Ö¸Êý£¨SI£©=¼Ó´Ì¼¤Ï¸°û¿×µÄA570Öµ/ÒõÐÔ¶ÔÕÕ¿×µÄA570Öµ¡£

¡¡¡¡ÖØ×éÈËHA-1ÖÊÁ£µÄ¹¹½¨ÓÃXbaIºÍBamHIÏÞÖÆÐÔÄÚÇÐø´Ó
¡¡¡¡pcDNA3.1-HA-1ÖÐÇÐÏÂ358 bp HA-1µÄcDNA£¬ÆäÖаüÀ¨Tϸ°û¾ö¶¨´ØVLHDDLLEA£¬¾­T4DNAÁ¬½Óø²åÈëpcDNA3.1/hisAµÄ¶à¿Ë¡λµãÖУ¬¾­¹ýøÇкͲâÐòÈ·¶¨ÖØ×éÊÇ·ñ׼ȷ£¬ÃüÃûΪpcDNA3.1/hisA-HA-1¡£
¡¡¡¡
¡¡¡¡×ªÈ¾DCÊÕ¼¯ÅàÑø7ÌìµÄDC£¬ÓÃRPMI 1640ÅàÑøÒºÏ´µÓ£¬µçת»º³åÒº£¨°´Eppendorf¹«Ë¾ÌṩµÄ»º³åÒºÅä·½ÅäÖ㬱£Ö¤Ï¸°ûÔÚÆäÖзõÓý30·ÖÖÓ£¬´æ»îÂÊÔÚ90£¥ÒÔÉÏ£©ÖØÐüϸ°û£¬µ÷ÕûŨ¶ÈΪ1¡Á106/ml£¬¼ÓÈëÖØ×éÖÊÁ££¬ÖÕŨ¶ÈΪ20 ¦Ìg/ml¡£µçתÌõ¼þΪ£º³£Î£¬µçѹ450 V£¬80΢Ã룬Âö³å1´Î¡£ÔÚ30·ÖÖÓÄÚÍê³É£¬¼ÓÈëÍêÈ«ÅàÑøÒº£¬ÖÃÓÚÎÂÏäÄÚ¼ÌÐøÅàÑø24-72Сʱ¡£Í¬Ê±ÓÃpEGFP-C1תȾ×÷¶ÔÕÕ£¬ÆÀ¼ÛDCµÄתȾЧÂÊ¡£

¡¡¡¡µ°°×±í´ïµÄWestern blot¼ì²âÓÚתȾ48СʱºóÊÕ¼¯Ï¸°û£¬ÓÃÒ»²½ÁѽⷨÌáÈ¡×ܵ°°×£¬¾­98¡æ±äÐÔ5·ÖÖӺ󣬴¹Ö±µçÓ¾¡£ÔÙÓõçתÒǽ«Äý½ºÖеĵ°°××ªÒÆµ½´×ËáÏËάĤÉÏ£¬5£¥ÍÑÖ¬ÄÌ·â±Õ£¬¼ÓHisµ¥¿Ë¡¿¹Ì壨1¡Ã1 000£©£¬4¡æ¹ýÒ¹£¬TBS-TҺϴ3´Î£¬ÔÙ¼ÓÈëHRP±ê¼ÇµÄ¶þ¿¹£¨1¡Ã200£©£¬37¡æºãÎÂÒ¡´²Ò¡¶¯2Сʱ£¬TBS-TÏ´µÓ3´Î£¬ÓÚ°µÊÒÖÐÓû¯Ñ§·¢¹â·¨ÏÔÉ«¡£

¹²2Ò³: 1 [2] ÏÂÒ»Ò³


ÄáĪµØÆ½¶Ô°¢ÌǰûÜÕÓÕµ¼HLª²60ϸ°ûµòÍö»úÖÆÓ°ÏìµÄÑо¿
D-ÄûÃÊÏ©¶ÔK562ϸ°ûÔöÖ³¼°µòÍöµÄÓ°Ïì
¹¤É̹ÜÀí | ¹¤¿ÆÂÛÎÄ | ²ÆÎñ¹ÜÀí | ¹ÜÀíѧ | ¹«¹²¹ÜÀí | ²ÆÕþ˰ÊÕ | ֤ȯ½ðÈÚ | »á¼ÆÉó¼Æ | ¼ÆËã»ú | ·¨ÂÉÂÛÎÄ | ҽҩѧ | ººÓïÑÔÎÄѧ
Éç»áÂÛÎÄ | ¹¤¿ÆÂÛÎÄ | Àí¿ÆÂÛÎÄ | ÎÄ»¯ÂÛÎÄ | ÒÕÊõÂÛÎÄ | ÎÄѧÂÛÎÄ | ÕÜѧÂÛÎÄ | ÕþÖÎÂÛÎÄ | Ó¢ÓïÂÛÎÄ | д×÷Ö¸µ¼ | ¼ÆËã»úÓ¦ÓÃ
www.zlunwen.com ÕÒÂÛÎÄÍø ® °æÈ¨ËùÓÐ ÍøÕ¾µØÍ¼